ProQR Therapeutics N.V. (PRQR) Earnings History
Net Loss13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
ProQR Therapeutics N.V. (PRQR) Earnings Overview
As of July 8, 2026, ProQR Therapeutics N.V. (PRQR) reported trailing twelve-month net income of -$46M, reflecting -11.8% year-over-year growth. The company earned $-0.43 per diluted share over the past four quarters, with a net profit margin of -265.2%.
Looking at the long-term picture, PRQR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2013.
ProQR Therapeutics N.V. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$109M net income, -395.0% margin), NTLA (-$395M net income, -609.9% margin), CRSP (-$569M net income, -16569.8% margin), PRQR has outperformed on profitability metrics. Compare PRQR vs EDIT →
PRQR Earnings vs Peers
Earnings metrics vs comparable public companies
PRQR Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$41M | -45.9% | -$42M | $-0.38 | -265.2% | -275.9% |
| 2024 | -$28M | +1.3% | -$30M | $-0.34 | -146.9% | -161.2% |
| 2023 | -$28M | +56.4% | -$32M | $-0.35 | -431.7% | -489.1% |
| 2022 | -$64M | -6.1% | -$65M | $-0.91 | -1792.5% | -1813.0% |
| 2021 | -$61M | -30.4% | -$57M | $-0.96 | -4549.8% | -4285.4% |
| 2020 | -$47M | +17.9% | -$42M | $-0.93 | -4525.3% | -4117.4% |
| 2019 | -$57M | -53.8% | -$57M | $-1.38 | -2935.6% | -2971.8% |
| 2018 | -$37M | +15.5% | -$36M | $-1.08 | -746.7% | -734.5% |
| 2017 | -$44M | -11.6% | -$40M | $-1.72 | - | - |
| 2016 | -$39M | -87.7% | -$40M | $-1.67 | -1713.5% | -1734.1% |
| 2015 | -$21M | -71.8% | -$27M | $-0.89 | -221.5% | -287.1% |
| 2014 | -$12M | -272.8% | -$16M | $-0.55 | -3874.4% | -5259.1% |
| 2013 | -$3M | - | -$3M | $-0.15 | - | - |
Download Data
Export PRQR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PRQR — Frequently Asked Questions
Quick answers to the most common questions about buying PRQR stock.
What is PRQR earnings per share (EPS)?
PRQR trailing twelve-month (TTM) diluted EPS is $-0.43, reflecting -11.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is ProQR Therapeutics N.V.'s net income?
ProQR Therapeutics N.V. (PRQR) trailing twelve-month net income is $-46M as of 2025. Earnings declined -11.8% year-over-year.
Is PRQR profitable?
PRQR is not currently profitable on a TTM basis, reporting a net loss of $-46M. Net margin is -265.2%. Investors should monitor for a return to profitability.
What is PRQR's earnings growth rate?
PRQR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are PRQR's profit margins?
ProQR Therapeutics N.V. net profit margin is -265.2%, operating margin is -275.9%, and gross margin is +83.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -58.8%.
Is PRQR growing earnings?
PRQR earnings are declining — EPS fell -11.8% year-over-year. TTM net income dropped to $-46M. This contrasts with the 5-year CAGR of N/A.
What was PRQR's best earnings year?
ProQR Therapeutics N.V.'s highest annual net income on record is $-3M, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were PRQR's earnings last quarter?
PRQR's most recent reported quarter was Q1 2026. Net income was $-14M with diluted EPS of $-0.13. For a full breakdown of all quarters, see the quarterly earnings table on this page.